- Spyre Therapeutics Announces $180 Million Private Placement
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
- Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
- Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
More ▼
Key statistics
On Wednesday, Spyre Therapeutics Inc (SYRE:NSQ) closed at 37.00, -22.87% below its 52-week high of 47.97, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.00 |
---|---|
High | 38.10 |
Low | 36.49 |
Bid | 14.80 |
Offer | 59.20 |
Previous close | 37.00 |
Average volume | 644.56k |
---|---|
Shares outstanding | 36.60m |
Free float | 32.01m |
P/E (TTM) | -- |
Market cap | 1.35bn USD |
EPS (TTM) | -75.04 USD |
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼